179 related articles for article (PubMed ID: 16683993)
1. Quality of life assessment in clinical practice in haemophilia treatment.
Gringeri A; Mantovani L; Mackensen SV
Haemophilia; 2006 Jul; 12 Suppl 3():22-9. PubMed ID: 16683993
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
McNaughton-Collins M; Walker-Corkery E; Barry MJ
J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
[TBL] [Abstract][Full Text] [Related]
3. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors.
Scalone L; Mantovani LG; Mannucci PM; Gringeri A;
Haemophilia; 2006 Mar; 12(2):154-62. PubMed ID: 16476090
[TBL] [Abstract][Full Text] [Related]
4. Quality of life and sports activities in patients with haemophilia.
VON Mackensen S
Haemophilia; 2007 Sep; 13 Suppl 2():38-43. PubMed ID: 17685923
[TBL] [Abstract][Full Text] [Related]
5. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life.
Wiklund I
Fundam Clin Pharmacol; 2004 Jun; 18(3):351-63. PubMed ID: 15147288
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
[TBL] [Abstract][Full Text] [Related]
7. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
8. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.
Brennan A; Ara R; Sterz R; Matiba B; Bergemann R
Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345
[TBL] [Abstract][Full Text] [Related]
9. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
Willke RJ; Burke LB; Erickson P
Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper.
Baiardini I; Bousquet PJ; Brzoza Z; Canonica GW; Compalati E; Fiocchi A; Fokkens W; van Wijk RG; La Grutta S; Lombardi C; Maurer M; Pinto AM; Ridolo E; Senna GE; Terreehorst I; Bom AT; Bousquet J; Zuberbier T; Braido F;
Allergy; 2010 Mar; 65(3):290-5. PubMed ID: 19930232
[TBL] [Abstract][Full Text] [Related]
11. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia.
Rentz A; Flood E; Altisent C; Bullinger M; Klamroth R; Garrido RP; Scharrer I; Schramm W; Gorina E;
Haemophilia; 2008 Sep; 14(5):1023-34. PubMed ID: 18665853
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness as an outcome in randomized clinical trials.
Hlatky MA; Owens DK; Sanders GD
Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
[TBL] [Abstract][Full Text] [Related]
13. Measuring patient-reported outcomes in haemophilia clinical research.
Globe D; Young NL; Von Mackensen S; Bullinger M; Wasserman J;
Haemophilia; 2009 Jul; 15(4):843-52. PubMed ID: 19473425
[TBL] [Abstract][Full Text] [Related]
14. How well does the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia?
Young NL; Bradley CS; Wakefield CD; Barnard D; Blanchette VS; McCusker PJ
Pediatr Blood Cancer; 2006 Sep; 47(3):305-11. PubMed ID: 16206209
[TBL] [Abstract][Full Text] [Related]
15. Translating the science of patient-reported outcomes assessment into clinical practice.
Osoba D
J Natl Cancer Inst Monogr; 2007; (37):5-11. PubMed ID: 17951224
[TBL] [Abstract][Full Text] [Related]
16. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index.
Dan AA; Kallman JB; Srivastava R; Younoszai Z; Kim A; Younossi ZM
Liver Transpl; 2008 Mar; 14(3):321-6. PubMed ID: 18306356
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
[TBL] [Abstract][Full Text] [Related]
18. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
[TBL] [Abstract][Full Text] [Related]
19. Comparing two measures of quality of life for children with haemophilia: the CHO-KLAT and the Haemo-QoL.
Bradley CS; Bullinger M; McCusker PJ; Wakefield CD; Blanchette VS; Young NL
Haemophilia; 2006 Nov; 12(6):643-53. PubMed ID: 17083516
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.
Sullivan MD; Anderson RT; Aron D; Atkinson HH; Bastien A; Chen GJ; Feeney P; Gafni A; Hwang W; Katz LA; Narayan KM; Nwachuku C; O'Connor PJ; Zhang P;
Am J Cardiol; 2007 Jun; 99(12A):90i-102i. PubMed ID: 17599429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
